Portal To Collate Data On Spurious Drugs In Works

New Delhi : India’s drug regulatory organization is planning to launch a unified portal to develop a digital drugs regulatory system. The system will maintain a database of drugs that are not standard quality or are spurious to build trust in their quality across domestic and global markets.

A unified portal which will maintain a database of drugs that are not of standard quality or are spurious is in the offing.

With an aim to build trust on the quality of drugs in the domestic and global markets, India’s drug regulatory organisation is all set to introduce a new unified portal for developing a digital drugs regulatory system (DRS).

The drug regulator has asked for suggestions from various government agencies over the proposed portal including all state drug controllers, customs, ministry of environment, drug manufacturing associations, Indian Council of Medical research, Bureau ofIndian Standards (BIS), among others.

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg